NORLIQVA is a Oral Solution in the Human Prescription Drug category. It is labeled and distributed by Cmp Pharma, Inc.. The primary component is Amlodipine.
| Product ID | 46287-035_63a6bb49-fb68-4351-be5f-a6b6e8f6b540 |
| NDC | 46287-035 |
| Product Type | Human Prescription Drug |
| Proprietary Name | NORLIQVA |
| Generic Name | Amlodipine |
| Dosage Form | Solution |
| Route of Administration | ORAL |
| Marketing Start Date | 2022-04-15 |
| Marketing Category | NDA / |
| Application Number | NDA214439 |
| Labeler Name | CMP Pharma, Inc. |
| Substance Name | AMLODIPINE |
| Active Ingredient Strength | 1 mg/mL |
| Pharm Classes | Calcium Channel Antagonists [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2022-04-15 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 46287-035 | NORLIQVA | amlodipine |
| 33342-015 | Amlodipine | Amlodipine |
| 33342-016 | Amlodipine | Amlodipine |
| 0615-6582 | Amlodipine Besylate | Amlodipine |
| 52652-5001 | Katerzia | Amlodipine |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() NORLIQVA 90522907 not registered Live/Pending |
CMP Development LLC 2021-02-10 |